Press release
Cytomegalovirus (CMV) Infections Market is projected to reach USD 3.12 billion by 2034
Cytomegalovirus (CMV) Infection
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71356
CMV is a widespread herpesvirus that causes lifelong latent infection. While often asymptomatic in healthy individuals, it poses significant risks to immunocompromised patients, including transplant recipients, HIV patients, and infants with congenital CMV. Complications include CMV viremia, pneumonitis, retinitis, gastroenteritis, hepatitis, and long-term neurologic impairment in newborns.
Key Market Highlights
• 2024 Market Size: USD 1.76 billion
• 2034 Forecast: USD 3.12 billion
• CAGR (2025-2034): 5.9%
• Largest Segment: Antiviral drugs (valganciclovir, ganciclovir)
• Fastest-Growing Segment: Prophylaxis in transplant patients & emerging biologics
Epidemiology & Clinical Insights
1. Global Prevalence
• CMV seroprevalence ranges from 40% to 90%, depending on region.
• Congenital CMV affects ~0.5-1% of live births, making it the most common congenital infection worldwide.
2. High-Risk Populations
• Solid organ transplant recipients
• Hematopoietic stem cell transplant patients
• Individuals with AIDS
• Premature infants and newborns
• Patients receiving immunosuppressive therapies
3. Diagnostic Tools
• PCR-based viral load testing
• CMV IgM/IgG serology
• Antigenemia assays
• Baby urine/saliva PCR for congenital CMV
Market Growth Drivers
1. Increasing Organ & Stem Cell Transplantation
Growing global transplant volumes significantly raise CMV prophylaxis and treatment demand.
2. Expansion of Congenital CMV Screening
Several countries now recommend newborn CMV screening, increasing early detection rates.
3. Advancements in Antiviral Therapy
New antivirals (e.g., letermovir) offer effective prophylaxis with fewer toxicities.
4. Rising Use of Immunosuppressive Drugs
Biologics and post-transplant immunomodulators increase vulnerability to CMV reactivation.
5. Growing Awareness of CMV-Associated Morbidity
Particularly in congenital CMV, which causes hearing loss, neurodevelopmental delay, and cerebral palsy.
Market Restraints
• Toxicity of existing antiviral agents (bone marrow suppression, renal injury)
• Limited treatment options for drug-resistant CMV
• Low awareness of congenital CMV in many countries
• Viral resistance due to prolonged antiviral exposure
• High cost of new prophylactic drugs
Market Opportunities
1. Novel Antiviral Therapies
New agents targeting CMV DNA terminase complex or polymerase with reduced toxicity.
2. Monoclonal Antibody & Vaccine Development
CMV vaccines are in mid- to late-stage clinical trials.
3. Expansion of Universal Newborn CMV Screening
Large-scale adoption expected in North America and Europe.
4. Personalized CMV Risk Stratification
AI-driven models predict post-transplant CMV reactivation.
5. Combination Therapy Strategies
Potential to reduce resistance and improve efficacy.
Segmentation Overview
By Treatment Type
• Antiviral drugs
o Ganciclovir
o Valganciclovir
o Foscarnet
o Cidofovir
o Letermovir (prophylaxis)
• CMV immunoglobulins
• Supportive therapy
• Pipeline biologics and vaccines
By Infection Type
• Congenital CMV
• Primary CMV infection
• CMV reactivation
• Transplant-associated CMV
By End User
• Hospitals
• Specialty transplant centers
• Pediatric care facilities
• Diagnostic laboratories
Explore Full Report here: https://exactitudeconsultancy.com/reports/71356/cytomegalovirus-cmv-infections-market
Regional Insights
North America - Largest Market
High transplantation rates, strong diagnostic infrastructure, and rapid adoption of new antivirals.
Europe - Advanced CMV Prevention Programs
Germany, UK, Spain, and France lead in congenital CMV research and transplant prophylaxis.
Asia Pacific - Fastest-Growing
Rising transplant volumes, laboratory expansion, and increasing awareness of congenital infections.
Latin America - Growing CMV Burden
Notable rise in pediatric CMV diagnosis and transplant-related infections.
Middle East & Africa - Emerging
Increasing investments in tertiary care and transplant centers.
Competitive Landscape
Key companies active in the CMV market include:
• Merck & Co.
• Roche
• Novartis
• Takeda
• Chimerix
• Genentech
• Gilead Sciences
• Atara Biotherapeutics
• Moderna (vaccine development)
• Pfizer (vaccine platform expansion)
Focus areas include antiviral innovation, CMV vaccines, biologics targeting resistant CMV strains, and maternal-infant prophylaxis.
Recent Market Developments
• Expanded approvals of letermovir for CMV prophylaxis in high-risk transplant patients
• Advancements in CMV vaccine candidates using mRNA and viral vector platforms
• Increased newborn screening initiatives in the U.S. and Europe
• Development of allogeneic T-cell therapies targeting drug-resistant CMV
• AI-based CMV viral load prediction tools entering clinical evaluation
Future Outlook (2025-2034)
The CMV Infections Market will grow steadily as:
• New antivirals reduce toxicity risks
• Vaccine candidates move closer to commercial approval
• Congenital CMV screening becomes standardized
• Transplant prophylaxis guidelines expand globally
• Cellular therapies emerge for resistant CMV
By 2034, the market is expected to reach USD 3.12 billion, supported by increasing CMV disease burden in both pediatric and immunocompromised populations.
This report is also available in the following languages : Japanese (サイトメガロウイルス(CMV)感染症市場), Korean (거대세포바이러스(CMV) 감염 시장), Chinese (巨细胞病毒 (CMV) 感染市场), French (Marché des infections à cytomégalovirus (CMV)), German (Markt für Zytomegalievirus (CMV)-Infektionen), and Italian (Mercato delle infezioni da citomegalovirus (CMV)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71356
Our More Reports:
Cidofovir Market
https://exactitudeconsultancy.com/reports/66303/cidofovir-market
Valganciclovir Hydrochloride Market
https://exactitudeconsultancy.com/reports/66324/valganciclovir-hydrochloride-market
Salivary Gland Infection Market
https://exactitudeconsultancy.com/reports/71151/salivary-gland-infection-market
Catheter-Related Bloodstream Infection Market
https://exactitudeconsultancy.com/reports/71721/catheter-related-bloodstream-infection-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cytomegalovirus (CMV) Infections Market is projected to reach USD 3.12 billion by 2034 here
News-ID: 4310119 • Views: …
More Releases from Exactitude Consultancy
Peanut Allergy Market is projected to reach USD 4.08 billion by 2034
The global Peanut Allergy Market was valued at USD 1.32 billion in 2024 and is projected to reach USD 4.08 billion by 2034, expanding at a strong CAGR of 11.9% from 2025 to 2034. Market growth is driven by rising prevalence of food allergies globally, increasing adoption of immunotherapy-based treatment approaches, and regulatory approvals of novel desensitization therapies for children and adolescents.
Download Full PDF Sample Copy of Market Report @…
Sarcoidosis Market is Projected to reach USD 3.2-3.7 billion by 2032, reflecting …
Market Overview
The Sarcoidosis market is growing steadily as awareness increases about this systemic inflammatory disease characterized by granuloma formation across organs such as the lungs, skin, lymph nodes, and eyes. Although many cases are mild, a significant portion requires long-term treatment due to organ involvement, especially pulmonary sarcoidosis. Rising diagnostic capabilities, improved imaging technologies, and expanding adoption of immunomodulatory therapies are fueling market growth.
The global Sarcoidosis market was valued at…
Anti-Glomerular Basement Membrane (Anti-GBM) Disease Market is projected to reac …
The global Anti-Glomerular Basement Membrane (Anti-GBM) Disease Market was valued at USD 612 million in 2024 and is projected to reach USD 1.09 billion by 2034, growing at a CAGR of 5.9% from 2025 to 2034. Market expansion is driven by improved diagnostic capabilities, early recognition of autoimmune renal diseases, increasing use of plasmapheresis and immunosuppressive therapies, and growing adoption of advanced biologics for refractory cases.
Download Full PDF Sample Copy…
Pyoderma Gangrenosum (PG) Market the market is expected to reach USD 550-650 mil …
Market Overview
The Pyoderma Gangrenosum (PG) market is expanding gradually as awareness increases about this rare, painful, and rapidly progressive neutrophilic dermatosis. PG commonly presents as ulcerative lesions that require prompt diagnosis and immunosuppressive therapy. Because of its rarity and frequent misdiagnosis, the market is driven largely by advancements in biologics, improved dermatology access, and rising clinical recognition.
The global PG market was valued at USD 350-400 million in 2024. With increasing…
More Releases for CMV
Cytomegalovirus (CMV) Infections Market Massive Growth opportunity Ahead
Introduction
Cytomegalovirus (CMV) is a common herpesvirus that affects people worldwide, often remaining latent in the body and reactivating under immunocompromised conditions. While typically asymptomatic in healthy individuals, CMV can cause severe complications in newborns, transplant recipients, and immunocompromised patients, making it a significant global healthcare burden.
With increasing awareness, advances in antiviral therapies, vaccines under development, and transplant-related CMV management, the CMV infections market is experiencing strong growth. The integration of…
Cytomegalovirus (CMV) Vaccine Market | Exploring Current Trends and Growth Statu …
Cytomegalovirus (CMV) Vaccine Market Outlook and Investment Analysis
What is the current outlook for the Cytomegalovirus (CMV) vaccine market?
The CMV vaccine market is seeing positive growth due to the increasing prevalence of CMV infections globally, particularly in immunocompromised populations such as organ transplant recipients and HIV patients. Moreover, the growing awareness of CMV's impact on newborns has contributed to the push for preventive vaccines. A few vaccines are in advanced clinical…
Cytomegalovirus (CMV) Test Market to Develop Rapidly by 2026
Cytomegalovirus (CMV) is a common virus that occurs widely among the population. In the U.S., 50%-85% of adults have been infected with cytomegalovirus (CMV). Most people who are infected with the virus do not experience any significant symptoms or health problems. CMV testing involves either a measurement of cytomegalovirus antibodies, immune proteins produced in response to CMV exposure, or the detection of the virus itself. CMV is found in many…
Global Commercial Cooking Device Market Forecast 2018-2025 CMV Sharper Finish, Q …
Market study on Global Commercial Cooking Device 2018 Research Report presents a professional and complete analysis of Global Commercial Cooking Device Market on the current market situation.
Report provides a general overview of the Commercial Cooking Device industry 2018 including definitions, classifications, Commercial Cooking Device market analysis, a wide range of applications and Commercial Cooking Device industry chain structure. The 2018's report on Commercial Cooking Device industry offers the global…
Cytomegalovirus (CMV) Market: Size, Status, Opportunity Analysis and Forecasts t …
A new independent 162 page research with title 'Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027' guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions like North America, Europe or Asia and important players/vendors such as Atara Bio, Biotest AG, Helocyte, Merck & Co., Novartis, Shire, ViraCyte With n-number of tables and figures examining the Cytomegalovirus (CMV) Market, the research gives…
Cytomegalovirus (CMV) Infection Treatment and Diagnosis Market Opportunity Analy …
Cytomegalovirus (CMV) is a virus that belongs to herpes virus family that remain dormant in the human body. CMV infection can occur in people of all ages worldwide. CMV is a communicable disease that spreads through body fluids such as saliva, blood, urine, semen, and breast milk. Presence of CMV infection can be detected by various testing methods based on which the global cytomegalovirus infection treatment and diagnosis market can…
